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Objectives The goal of this study was to assess serial changes in patient health-related quality of life (HRQOL) over time
and identify predictors of patient benefit.
Background Severe aortic stenosis reduces the length and quality of a patient’s life. Transcatheter aortic valve implantation
(TAVI) is superior to standard medical therapy and noninferior to surgical aortic valve replacement for 1-year
mortality. HRQOL is an important outcome measure for which there is limited evidence in TAVI populations.
Methods A total of 102 patients (mean age 80  0.6 years; 49% male) undergoing TAVI consented to participate. Two
HRQOL questionnaires—the social functioning (SF)-12v2 with physical component summaries (PCS) and mental
component summaries (MCS) and the EQ-5D (with a visual analog scale [VAS])—were completed at baseline,
30 days, 6 months, and 1 year according to the recommendations of the Valve Academic Research Consortium.
A SF-6D utility measure was calculated from the SF-12 survey.
Results HRQOL significantly improved over 1 year (PCS p  0.02; EQ-5D p  0.02; VAS p  0.01; SF-6D p  0.03), be-
coming similar to age-adjusted U.S. population norms. The greatest change occurred from baseline to 30 days
(p  0.001), with further significant improvements to 6 months (p  0.01). An insignificant decline occurred
between 6 months and 1 year (p  0.05), but a linear pattern of change remained for PCS, EQ-5D, and VAS
(p  0.05). Male sex (SF-6D p  0.01) and increased operator experience (PCS, EQ-5D, and VAS p  0.05) were
independent predictors of a greater improvement in HRQOL.
Conclusions HRQOL significantly improved early after TAVI and was maintained out to 1 year. Patient factors, procedural
complications, and operator experience are predictors of health benefit at 1 year. (J Am Coll Cardiol 2012;59:
1672–80) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.035Symptomatic aortic stenosis (AS) reduces the quality and
duration of an individual’s life. Transcatheter aortic valve
implantation (TAVI) is indicated as a treatment for the
large number of patients with severe AS unsuitable for
surgical aortic valve replacement (SAVR) (1). Clinical trial
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2012, accepted January 25, 2012.and registry data have demonstrated high procedural suc-
cess, significantly improved survival compared with medical
therapy, and noninferiority in mortality to SAVR at 1 year
(2–4). Health-related quality of life (HRQOL) assessments
are important clinical outcome measures of medical treat-
ments. The Valve Academic Research Consortium recom-
mended that quality of life questionnaires be used as a
TAVI clinical benefit endpoint and that they should be
conducted over 4 separate time points (baseline, 30 days, 6
months, and 1 year) (5). Quality of life is particularly
relevant for TAVI patients; in an elderly population with
multiple comorbidities, the absolute survival benefit may be
less substantial, increasing the importance of quality-
attained years. In addition, identification of particular risk
factors and predictors of HRQOL would allow the “heart
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benefits from this high-risk procedure.
Health utility values are a measure of preferences for
health states, which are essential for the calculation of
quality-adjusted life-years (QALYs) within the framework
of cost-utility analyses. Cost-utility analyses are the pre-
ferred approach, with QALYs the preferred metric of
organizations charged with evaluating the cost-effectiveness
of medical technologies for the purpose of healthcare resource
allocation and decision making (6).
Quality of life data on TAVI populations are sparse (7,8),
nd at the time of writing, only the PARTNER study has
ublished HRQOL results over the range of recommended
ime points (9), with no reports of health utility values for
his patient group. Health utility values, especially multiple
ssessments over a long time period, are important to allow
ost-effective analyses and decision analytical modeling to
e undertaken.
The goals of this study were to assess serial changes in
RQOL and health utility at 30 days, 6 months, and 1 year
fter TAVI and to identify the clinical variables that predict
atient benefit.
ethods
total of 102 patients who underwent TAVI at our
nstitution between May 2008 and May 2010 provided written
nformed consent to the study, which was approved by the
nstitutional ethics committee and performed in accordance
ith the Declaration of Helsinki. Patient selection for TAVI
as performed by a multidisciplinary heart team that included
cardiologist, cardiothoracic surgeon, and cardiac anesthetist.
sing echocardiography, severe AS was defined as a peak
elocity4 m/s or a calculated aortic valve area0.8 cm2. All
individuals were symptomatic and deemed unsuitable for
SAVR due to high calculated surgical risk (EuroSCORE
20) or inoperable comorbidities. Pre-operative assessments
included invasive angiography of the coronary and iliac arteries
and transesophageal echocardiography. Patients were deemed
unsuitable for TAVI if the aortic annulus was 20 or 27
m. Exclusion criteria were the inability to comprehend
nglish language or impaired cognition.
ranscatheter aortic valve implantation. TAVI was per-
ormed under general anesthesia using the 18F CoreValve
evalving System (Medtronic, Inc., Minneapolis, Minne-
ota) as described previously (10). A transfemoral approach
as used where possible, with percutaneous access and
losure. A surgical subclavian approach was performed in
atients without suitable femoral access. Aortic valvulo-
lasty under rapid pacing control was followed by
oreValve implantation (26 or 29 mm) with post-dilation
s required. The primary operator was identical for all
rocedures, and the results reflect all cases sequentially
erformed after proctorship.
uality of life assessments. HRQOL was assessed using 2eneric, validated questionnaires: the SF-12v2 health out- homes questionnaire (Quality-
etric Inc., Lincoln, Rhode Is-
and) and the EQ-5D question-
aire (EuroQOL). Each patient
ompleted a questionnaire at
aseline, 30 days, 6 months, and
year. The initial survey was
onducted by interview with a
rained health care specialist, and
ater time points were completed
y postal or telephone survey.
atient characteristics, comorbi-
ities, New York Heart Associa-
ion (NYHA) functional class,
rocedural risk factors, and vari-
bles were collected before
AVI. Post-operative complica-
ions (e.g., vascular hemorrhage,
ermanent pacemaker implanta-
ion) and mortality were collected
ost-TAVI.
The SF-12v2 is based on the
6-item Short-Form Health
urvey but is shorter and simpler
o complete and is thus more
uitable to an elderly population.
t uses 8 dimensions to assess
RQOL: physical functioning (PF), role physical (RP),
odily pain (BP), general health (GH), vitality (VT), social
unctioning (SF), role emotional (RE), and mental health
MH). Responses applied to the patient’s health over the
revious 4 weeks. These responses were then graded and
cored from 0 to 100, with a higher score reflecting a better
RQOL. In addition, 2 separate component summary
cores are provided, distinguishing between physical (phys-
cal component score [PCS]) and mental (mental compo-
ent score [MCS]) health.
EQ-5D and SF-6D are 2 health-based utility measures.
tility measures typically provide an index (quality of life
eighting) between 0 and 1, where 1 reflects full health and
, death. Utility values are combined in economic evalua-
ions with survival data to calculate QALY gains from new
reatments and technologies. EQ-5D uses 5 domains to
ssess health states: mobility, self-care, usual activities,
ain/discomfort, and anxiety/depression. It is scored using
he U.K. population tariff time-tradeoff valuation exercise.
atients also completed a visual analog scale (VAS) of worst
maginable (0) to best possible (100) health. Answers
pplied to the day of completing the questionnaire. SF-6D
s a utility-based measure that is calculated using the SF-12
cores converted to SF-6D utility scores using a U.K. tariff
11). This provides an additional domain (vitality) and
ifferent recall period (4 weeks) from the EQ-5D. Differ-
nces in the change of scores suggest that SF-6D has a
Abbreviations
and Acronyms
ANOVA  analysis of
variance
AS  aortic stenosis
BP  bodily pain
GH  general health
HRQOL  health-related
quality of life
MCS  mental component
score
NYHA  New York Health
Association
PCS  physical component
score
QALY  quality-adjusted
life-year
RE  role emotional
RP  role physical
SAVR  surgical aortic
valve replacement
SF  social functioning
TAVI  transcatheter aortic
valve implantation
VT  vitalityigher sensitivity in severe disease processes (12).
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Serial Change in Quality of Life 1 Year After TAVI May 8, 2012:1672–80In this TAVI population who were in generally poor
health, the use of both EQ-5D and SF-12 surveys is
complementary; EQ-5D is more suitable for a population
with poor health because it demonstrates a ceiling effect in
moderately severe health conditions, whereas SF-12 report-
edly underestimates the severity of health status in poorer
health groups but does not demonstrate a ceiling effect (12).
Statistical analysis. Continuous data are presented as
mean  SD and categorical data as frequency and percent-
age. Normality was determined by using the Shapiro-Wilks
test and Q-Q plots. Comparative statistics used were the
Student t test and Wilcoxon signed rank test as appropriate.
All paired comparisons between baseline measurements and
the various time points were performed analysis by analysis,
excluding unpaired results. The chi-square test was used for
categorical comparisons. Repeated measures analysis of
variance (ANOVA) general linear model was applied to
detect changes over the 4 time points and differences
between subject factors. Predictors of the 1-year health
scores were assessed by using individual linear regression
analysis, with baseline scores entered as a covariate factor.
Individual variables with a p value 0.1 were entered into
the multivariate general linear model. All statistical analyses
were performed using PASW software version 17.0 (SPSS
Inc., Chicago, Illinois); a 2-sided significance level of p 
0.05 was considered statistically significant.
Results
All 102 patients completed baseline HRQOL question-
naires. Three patients had valvuloplasty instead of TAVI,
giving a 97% procedural success. The study population
therefore consisted of 99 patients (mean age 80  6 years;
49% male); clinical and procedural characteristics are re-
ported in Table 1. All-cause mortality was consistent with
the published literature; 3 (3%) at 30 days, 7 (7%) at 6
months, and 20 (20%) at 1 year (12). Three patients (3%)
were unable (due to cognitive decline) and 4 (4%) unwilling
to complete all 4 time point questionnaires. Incomplete
questionnaires, including those as a result of patient death,
were excluded from subsequent time point ANOVA anal-
ysis. Table 2 shows the health score results for each survey
according to the Valve Academic Research Consortium–
recommended time points, with the U.S. population norms
stratified for age (80 to 89 years) to allow comparison with
an equivalent age group of healthy individuals (13).
SF-12 health scores. The separate health component
scores over the 4 different time points are shown in Figure 1.
Components that increased significantly from baseline to 30
days included: PF (27.8  7 vs. 33.6  9; p  0.001), RP
31.8 8 vs. 35.8 10; p 0.006), BP (38.9 14 vs. 45.9
2; p  0.001), GH (33.4  10 vs. 40.3  11; p  0.001),
T (36.8  9 vs. 41.2  10; p  0.006), and MH (45.2 
1 vs. 48.5  11; p  0.027). SF (37.4  14 vs. 39.7  13;
p  0.22) and RE (39.2  12 vs. 40.8  15; p  0.75)
improved but not significantly. At 6 months, there was a mfurther increase from 30 days in PF (36.5  12; p 0.001),
RP (39.3  10; p  0.001), VT (43  11; p  0.002), SF
(42.8  15; p  0.06), and RE (42.6  13; p  0.67). BP
and GH scores did not increase further but remained
significantly higher than baseline (45.4 13 [p 0.02] and
40.8  11 [p  0.001]). One-year measurements revealed a
nonsignificant (p  0.05) decrease in all components when
ompared with 6-month scores, with a sustained improve-
Baseline Demographic, Clinical, and ProceduralCharacteristics of t e TAVI Population (N  99)Table 1 Baseline Demogr hic, Clini al, and ProceduralCharacteristics of the TAVI Population (N  99)
Clinical characteristics
Age (yrs) 80 6
Male 48 (49)
EuroSCORE (logistic %) 20 13
Smoker
Never 34 (34)
Ex-smoker 63 (64)
Smoking 2 (2)
Diabetic 33 (33)
Renal disease* 9 (9)
MI 39 (39)
AF 26 (26)
COPD 23 (23)
CVD 9 (9)
PVD 15 (15)
CABG 28 (28)
Angina (CCS class)
0 62 (62)
1 4 (4)
2 12 (12)
3 18 (18)
4 3 (3)
NYHA functional class
1 0 (0)
2 13 (13)
3 60 (61)
4 26 (26)
Pulmonary hypertension 15 (15)
Porcelain aorta 15 (15)
Procedural variables
Access
Subclavian 8 (8)
Femoral 91 (92)
Valve (mm)
26 26 (26)
29 73 (74)
Mortality (30-day) 3 (3)
Periprocedural MI 0 (0)
Stroke 2 (2)
Vascular hemorrhage 4 (4)
Transfusion 26 (26)
Acute kidney injury 1 (1)
Permanent pacemaker 20 (20)
Values are mean  SD or n (%). *Estimated glomerular filtration rate 30 ml/min/1.73 m2.
AF  atrial fibrillation; CABG  coronary artery bypass graft; CCS  Canadian Classification
Score of angina; COPD  chronic obstructive pulmonary disease; CVD  cerebrovascular disease;
YHA  New York Health Association; MI  myocardial infarction; PVD  peripheral vascular
isease; TAVI  transcatheter aortic valve implantation.ent compared with baseline scores in PF (34.9  10; p 
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0.003), and VT (40.2  10; p  0.03). Repeated measures
NOVA showed a significant improvement over the 4 time
oints to 1 year for all PCS scores (PF, RP, BP, and GH)
ut not for the MCS scores (VT, MH, SF, and RE).
The summary score for physical health (PCS) increased
rom baseline (29.5  9) to 30 days (36.3  9; p  0.001)
and 6 months (38.3  11; p  0.001). One-year PCS,
lthough lower than the 6-month score, was still signifi-
antly higher compared with baseline (34.4  10; p 0.02)
Table 2). Repeated measures ANOVA in those patients
ho completed surveys at all 4 time points (n  65)
Health Scores for Each Health Survey AccordingTime Points (Baseline, 30 Days, 6 Months, andTable 2 He lth S ores for Each Health SurvTime Points (Baseline, 30 Days, 6
Health Survey U.S. Norm*
Baseline
(n  99)
PCS 37.3 3 29.5 9
MCS 51 3 45.4 12
EQ-5D 0.66 0.2 0.54 0.3
VAS 0.53 7 51.1 21
SF-6D 0.72 0.1 0.60 0.1
Values are mean  SD. *U.S. norms are reported for a U.S. populatio
§p  0.05: p values are reported for a change in health for each time
MCS  mental component score; PCS  physical component scor
VAS  visual analog scale.
Figure 1 Changes in SF 12 Health Component Scores After TA
Time points are represented by different-colored bars. BP  bodily pain; GH  genera
RE  role emotional; RP  role physical; SF  social functioning; VT  vitality. P valuemonstrated a significant linear (p  0.03) and quadratic
inverted U-shaped curve p  0.001) relationship over time
Table 3). Overall MCS showed no significant change from
aseline to any of the individual time points (30 days p 
.47; 6 months p  0.71; and 1 year p  0.58) (Table 2),
hich was confirmed on repeated measures ANOVA (p 
.13) (Table 3).
tility assessment scores. EQ-5D and VAS scores in-
reased significantly from baseline to 30 days (0.54 0.3 vs.
.65  0.3 [p  0.001] and 51.1  21 vs. 61.4  21 [p 
.001], respectively). These scores improved further at 6
onths (0.68  0.3 [p  0.006] and 68.2  20 [p 
he VARC- Recommendedar) and U.S. Population Normscording to the VARC- Reco mended
hs, and 1 Year) and U.S. Population Norms
Time Point
30 Days
(n  90)
6 Months
(n  70)
1 Year
(n  65)
36.3 9† 38.3 11‡ 34.4 10§
46.4 13 47.4 11 46.9 11
0.65 0.3‡ 0.68 0.3§ 0.65 0.3§
61.4 21† 68.2 20‡ 61.5 21§
0.66 0.1‡ 0.68 0.1‡ 0.63 0.1§
fied according to age (80 to 89 years). †p  0.001, ‡p  0.01,
compared with baseline by using the paired t test.
social functioning; VARC  Valve Academic Research Consortium;
h; MH  mental health; NS  not significant; PF  physical functioning;
epeated measure analysis of variance: *p  0.05, **p  0.01, ***p  0.001.to t1 Yeey Ac
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0.3 [p  0.94] and 61.5  21 [p  0.70]) (Table 2).
One-year measures remained significantly higher than base-
line for both EQ-5D and VAS scores (p  0.02 and p 
0.01). Repeated measures ANOVA demonstrated a signif-
icant linear and quadratic relationship over the 4 time points
for both EQ-5D (p  0.04 and p  0.02) and VAS (p 
0.02 and p 0.002) scores (Table 3). SF-6D increased from
baseline to 30 days (0.60  0.1 vs. 0.66  0.1; p  0.001)
and was maintained at 6 months (0.68  0.1; p  0.001)
nd 1 year (0.63  0.1; p  0.03) (Table 2). Repeated
easures ANOVA again showed a significant quadratic
elationship over the 4 time points (p  0.004) (Table 3).
RQOL changes related to patient and procedural
haracteristics. All variables were assessed for predictors of
hange in HRQOL from baseline to 1 year using a general
inear model. Age was considered as a linear variable as well
s being categorized into groups of 80 years or 80 years.
ndependent predictors of HRQOL change at 1 year are
eported for the separate questionnaires in Table 4. MCS
alues have not been reported because there were no
ignificant predictors of change.
Male sex was an independent predictor of greater im-
rovement in HRQOL at 1 year (SF-6D) (Table 4). There
as no sex difference in HRQOL scores at baseline, but at
year, males had significantly higher HRQOL compared
ith females (SF-6D 0.69  0.1 vs. 0.58  0.1; p  0.001)
(Fig. 2A). Males had significantly worse baseline left ven-
tricular ejection fraction (p  0.004) and higher incidence
of previous myocardial infarction (p  0.001), with no
difference between other characteristics (EuroSCORE, age,
or operation order).
Health changes also differed between age groups. The
younger age group (80 years) compared with the older
group (80 years) reported lower baseline health scores
(EQ-5D 0.45  0.3 vs. 0.58  0.3 [p  0.04]; VAS 43 
25 vs. 54 20 [p 0.02]; and SF-6D 0.56 0.1 vs. 0.61 0.1
[p  0.03], respectively) with no difference between their
health scores at 1 year (EQ-5D 0.67  0.3 vs. 0.63  0.3
[p  0.51]; VAS 58  21 vs. 64  20 [p  0.29]; and
Serial Change in Health Scores for Each Health6 Months, and 1 Year) in Pati nts Who CompleteTable 3 Serial Change in Health Scores for Ea6 Months, and 1 Year) in Patients W
Health Survey
Time Po
Baseline
(n  65)
30 Days
(n  65)
PCS 32.2 9 37.4 9
MCS 45.2 10 45.8 13
EQ-5D 0.59 0.3 0.70 0.3
VAS 52.8 19 64.6 20
SF-6D 0.61 0.1 0.67 0.1
Values are mean  SD. *p values are reported for a change in health
p values reflect an inverted U-shaped curve, where linear p values repr
point questionnaires entered into the analysis.
Abbreviations as given in Table 2.SF-6D 0.64  0.1 vs. 0.63  0.1 [p  0.70]) (Fig. 2B).Other than prior coronary artery bypass graft predicting a
greater improvement in HRQOL, no other specific pre-
existing comorbidity predicted 1-year HRQOL. Those
patients with higher baseline NYHA and angina class had a
lower baseline HRQOL, although these findings were not
significant (p  0.55 and p  0.48, respectively). Pre-
operative NYHA functional classes III and IV patients did,
however, experience a smaller increase in their HRQOL
score compared with those individuals in NYHA classes I
and II (Table 4).
HRQOL changes related to operative variables. Opera-
tor experience affected HRQOL (Table 4). Operative order
was separated into 2 groups: the first 50 (group 1) and
subsequent 49 (group 2) procedures. Patients in group 2 had
a greater increase in all 4 health survey scores (PCS,
EQ-5D, VAS, and SF-6D) at 1 year. Group 2 patients had
y (Baseline, 30 Days,stionnaires at all 4 Time Pointsalth Su vey (B seline, 30 Day ,
mpleted Questionnaires at all 4 Time Points
*p Value
onths
65)
1 Year
(n  65) Quadratic Linear
 11 36.5 11 0.001 0.03
 11 47.2 11 0.15 0.13
 0.3 0.67 0.3 0.02 0.04
 21 63.3 21 0.002 0.02
 0.1 0.64 0.1 0.004 0.14
ere calculated by repeated measures analysis of variance. Quadratic
linear trend. Numbers reflect the patients who completed the 4 time
Predictors of 1-Year Quality of LifeTable 4 Predictors of 1-Year Quality of Life
Univariate Analysis Mutivariate Analysis
Beta
Standard
Coefficient p Value
Beta
Standard
Coefficient p Value
PCS
Age group 3.33 0.07 3.01 0.09
Operation order 10.90 0.002 4.05 0.05
CABG 4.56 0.04 3.47 0.07
NYHA functional class 4.00 0.02 1.83 0.18
EQ-5D
Operation order 12.6 0.001 4.017 0.001
Male 3.06 0.09 0.69 0.41
Vascular complication 5.94 0.02 9.68 0.03
NYHA functional class 2.81 0.07 2.14 0.13
VAS
NYHA functional class 2.69 0.07 2.05 0.14
Operation order 5.74 0.02 4.97 0.03
SF-6D
Operation order 7.08 0.01 1.11 0.34
Male 10.10 0.003 2.84 0.01
NYHA functional class 4.95 0.01 2.53 0.09
p values represent the univariate and multivariate general linear regression model and the beta
standard coefficients. Individual variables were entered into a multivariable model if the p valueSurved Quch H
ho Co
int
6 M
(n 
40.5
46.7
0.71
64.8
0.69
and w
esent awas 0.1.
Abbreviations as in Tables 1 and 2.
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group 1, which increased further, becoming significantly
different at 1 year (PCS p  0.003; VAS p  0.02; EQ-5D
 0.001; and SF-6D p  0.01) (Fig. 2C). Vascular
emorrhage was an independent predictor of lower EQ-5D
t 1 year, with no other specific procedural complication
transfusion or aortic regurgitation) resulting in a significant
ecline in HRQOL scores (Table 4).
iscussion
n a high-risk AS population, we found serial improvements
n quality of life sustained over 1 year after TAVI. Benefit
as seen early (at 30 days post-procedure) and increased
urther at 6 months. An insignificant drop in health status
ccurred between 6 months and 1 year, which seemed to be
elated to both patient and procedural factors. Male sex was
n independent predictor of a greater increase in health
core from baseline to 1 year. We have also shown for the
rst time that the “learning curve” of operator experience
ffected the health benefits for patients, independent of
ther procedural factors or complications.
Quality of life is an important clinical outcome measure of
AVI because patients are elderly, often frail, and have
ultiple comorbidities. This study demonstrated the change
n HRQOL over time post-TAVI, with the greatest change
rom baseline being observed at the 30-day time point. This
nding may be explained by certain early benefits from the
ess invasive nature of TAVI (compared with SAVR), such
s shorter hospital stay, rapid hemodynamic response, and
educed mortality (3–5,7–15). Health scores increased fur-
her from 30 days to 6 months, with an insignificant decline
etween 6 months and 1 year for all surveys. In separate
tudies, HRQOL post-TAVI has previously been shown to
mprove at the individual time points of 30 days, 5 months,
r 1 year (7,8,16) and over a series of time points (9), but
ur study is the first, to our knowledge, to show a pattern
f health change over time as recommended by the Valve
cademic Research Consortium for both health and
tility measures. When compared with the age-matched
eneral U.S. population norms, the baseline health of our
AVI population seemed considerably worse. This im-
roved up to 6 months, where the average health was
etter than the general U.S. norm for PCS, EQ-5D, and
AS with similar scores in MCS and SF-6D. The small
rop in reported health between 6 months and 1 year,
hich although statistically insignificant, may reflect a
ecline in health that could become significant over a
onger time period (e.g., 2 years). This observation is
mportant in determining the health outcome post-TAVI
nd would suggest that future studies should involve
ong-term (1 year) follow-up.
An important finding of this study is that various sub-
roups within the TAVI population had different health
esponses. One of the major driving forces in the develop-
ent of TAVI was to aid in the treatment of elderly patients mith severe AS, who with high levels of morbidity and
ortality were not receiving SAVR (17). This observation
as despite the evidence that SAVR improves relative
urvival (18,19) and quality of life in octogenarians (20,21).
ur study is concordant with that of Bekeredjian et al. (22),
hich found that HRQOL improves post-TAVI in indi-
iduals age 80 years. In addition, we demonstrated that
ounger patients (age 80 years) actually have lower base-
ine health scores yet gain equal benefits from the procedure.
his is important because in the future, TAVI may be
erformed on a younger population. Higher baseline health
cores in the older age group may seem counterintuitive, but
ge itself does not affect HRQOL. It is the associated
iseases and loneliness which prevail in the elderly that
educe HRQOL (11). Our age groups (80 and80 years)
ad similar baseline comorbidities, and thus the elderly
opulation may perceive their health to be relatively higher
ue to lower expectations.
Females with AS have a decreased survival compared
ith males that is predominantly due to lower referral rates
or SAVR because once operated on, they have similar
ortality outcomes (23). TAVI data have not demonstrated
ny sex differences in clinical outcomes such as mortality or
troke, but no one has previously assessed this in relation to
RQOL as an outcome measure. Despite having a slightly
igher rated baseline health, females improved less signifi-
antly than their male counterparts, with the difference
ecoming significant at 1 year. This finding was not related
o any differences in baseline demographic characteristics or
o the operative procedure. Although not formally assessed
n this study, it may reflect a greater prevalence of frailty in
lderly female patients.
Operator experience has been reported to adversely affect
rocedural success, cardiovascular outcomes, and 30-day
urvival after the TAVI procedure as a result of a learning
urve and device developments (24,25). We describe for the
rst time the impact of this learning curve on HRQOL as
clinical outcome. Multivariate analysis showed operator
xperience to be a predictor of health outcomes in 3 of 4
ealth surveys, independent of baseline patient characteris-
ics (age, sex, and comorbidities) and procedural complica-
ions. A change in the patient selection process that is not
dentified by using standard risk scores or associated comor-
idities such as frailty could have contributed to this
bservation, as may be suggested by the insignificantly
igher baseline health scores of patients in group 2. Because
n identical valve device was used in all subjects and the
rocedure was performed by a single primary operator,
evice technological developments are excluded as a possible
xplanation for a difference in health benefit over time.
lthough not identifying a “critical number” of procedural
xperience required, this finding does provide further evi-
ence to support the training and performance of TAVI in
igh-volume centers with experienced operators to maxi-
ize the improvement in patient outcomes.
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Serial Change in Quality of Life 1 Year After TAVI May 8, 2012:1672–80Patient selection remains one of the most challenging
areas of TAVI practice. Our results provide evidence that a
higher NYHA functional class predicts a less substantial
improvement in health, whereas previous patient coronary
artery bypass graft leads to a greater improvement in
HRQOL. These factors, if confirmed in larger studies,
could contribute toward the heart teams’ TAVI patient
selection criteria and aid the decision-making process for
the individual patient.
The published TAVI data have demonstrated improve-
ment in patient survival and symptoms, but it remains a
costly procedure with a significant post-procedural risk of
death, vascular hemorrhage, and stroke (3). Cost-
effectiveness and the calculation of QALYs will therefore
form an important part of health policy planning and
outcome measurement in TAVI clinical practice. Until now,
Figure 2 Patterns of Health Change Over 1 Year According to
(A) Change over time for SF-12, EQ-5D, visual analog scale (VAS), and SF-6D acco
(B) Change over time for SF-12, EQ-5D, VAS, and SF-6D for individuals age 80 yno health utility measures have been reported in a TAVI tpopulation. In our study, a significant improvement oc-
curred over 1 year for both utility measures, which also
showed a similar pattern of change. Further investigation is
required to establish if the improvement in health of our
study population, when combined with improved mortality
rates, will indicate a health economic benefit of TAVI.
Study limitations. Although the study cohort was repre-
sentative of a typical TAVI population, this was a single-
center study in the United Kingdom and, as with all quality
of life studies, it should be interpreted in the context of the
local population. The interpretation of the multivariate
analysis is limited by a reduced sample size at 1 year (n 
5). As future TAVI numbers increase, larger studies will be
equired to validate our findings. A surgical comparison
roup was not recruited given the difficulty in matching to
TAVI population for age, comorbidities, and risk factors;
oup Analysis
to sex.
r 80 years. Continued on next page.Subgr
rding
ears ohis difficulty was a consequence of the current guidelines
1679JACC Vol. 59, No. 19, 2012 Fairbairn et al.
May 8, 2012:1672–80 Serial Change in Quality of Life 1 Year After TAVIfor TAVI patient selection. Incomplete questionnaires sec-
ondary to cognitive decline (3%) may indicate a reduced
quality of life that has not been calculated. This study was
not designed to perform a cost-effectiveness analysis or
calculate QALYs from the health utility data. Ideally, any
future study should combine both aspects in a multicenter,
international registry to provide more comprehensive infor-
mation to allow future health policy planning.
Conclusions
Quality of life improved early after TAVI and was main-
tained out to 1 year. Population subgroups respond differ-
ently to TAVI (e.g., males had larger health improvements).
Increased operator experience was a predictor of greater
Figure 2 Continued
(C) Change over time for SF-12, EQ-5D, VAS, and SF-6D according to operation
order (group 1  first 50 cases; group 2  last 49 cases). PCS  physical
component score.improvement in patient’s quality of life, independent ofother patient or procedural variables. Health utility mea-
sures showed a similar pattern of increased patient health
out to 1 year and could in the future be combined with
mortality data to produce a comprehensive health benefit
model for TAVI.
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